First Trust NYSE Arca Biotech Index Fd

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Veracyte Receives Medicare Coverage for Bladder Cancer Test, Orders Open June 1

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Illumina CEO joins China delegation, stock price rises

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Leqembi® Iqlik™ PDUFA date updated to August 24th

FDA Prioritizes Review of LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's Disease

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

LABU

SBIO

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Arcadian Asset

S&P 500

BAYRY

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)

ENTA

ARKG

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Ark Genomic Revolution ETF

VG Health

Enanta Pharma's RSV Bet And Immunology Ambitions

BCRX

QNRX

The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and ATR-12. The U.S. is expected to lead in market size, with an increase in diagnosed cases due to better diagnostics. Current treatments are mainly symptomatic, highlighting the need for effective, targeted therapies. The development of these new drugs presents significant opportunities in addressing the unmet medical needs of Netherton syndrome patients.

prnewswire

BioCryst Pharma

Quoin Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Azitra

QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

IMUX

BIIB

Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Skerjanec, who will remain a board member. Bonney has a strong background in the pharmaceutical industry, having previously held senior roles at Biogen and served as CEO of Cubist Pharmaceuticals, leading its sale to Merck for approximately USD 9.5 billion.

PUBT

Immunic

Merck

Biogen

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

BMRN

BioMarin Pharmaceutical (BMRN) has seen a decline in its stock price, down 4% in a day and 17% over three months, raising concerns about its valuation. Currently priced at $49.67, analysts estimate a fair value of $89.96, indicating potential undervaluation. However, there is significant disagreement among analysts regarding future earnings projections. The company's high P/E ratio of 35.7x compared to industry averages suggests valuation risks. Investors are advised to consider both opportunities and risks before making decisions.

Simplywall

BioMarin Pharma

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

GILD

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Gilead Sciences

Gilead Sciences, Inc.

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

MEDP

IDNA

LABD

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

Medpace

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

Direxion S&P Biotech Bear 3X

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

NAII

Natural Alternatives International reported a Q3 FY26 net loss of $4.31 million, a 97% increase from $2.19 million a year prior. Net sales rose 23% to $35.48 million, but gross profit fell to $383,000, reducing gross margin to 1.1%. The operating loss widened to $4.01 million. For the nine months, net sales increased 13% to $108.01 million, with a narrowed operating loss of $5.58 million. Management anticipates higher fourth-quarter sales but expects continued net losses and plans to sell its headquarters to improve liquidity.

Natural Alternatives

Natural Alternatives’ Q3 FY26 net loss widens 97% to $4.31 million

NNNN

Anbio Biotechnology's shareholders approved several resolutions at an extraordinary general meeting on May 15, 2026. Key decisions included a reduction in par value of shares, an increase in authorized share capital to USD 3,000, and endorsement of new Class B ordinary shares with enhanced voting rights. Share consolidation authority was also granted, although no specific consolidations were confirmed.

Anbio Biotechnology

Anbio Biotechnology shareholders approve restated charter at extraordinary general meeting

AVTR

Avantor has appointed Gerard (Jerry) Porreca as executive vice president of quality and regulatory, effective May 19, 2026. He will oversee global quality assurance and regulatory affairs. Porreca previously worked at Getinge and held senior roles at Becton Dickinson, C.R. Bard, and Smith+Nephew.

Avantor

Becton Dickinson and

Smith and Nephew

Avantor names Gerard Porreca executive vice president, quality and regulatory

CMND

Clearmind Medicine will implement a 1-for-10 reverse stock split on May 21, 2026, to comply with Nasdaq's minimum bid price requirement. The number of issued and outstanding shares will decrease from 10,190,337 to approximately 1,019,033, with fractional shares rounded up. Adjustments will also be made to outstanding options and warrants accordingly.

Clearmind Medicine

Clearmind Medicine to execute 1-for-10 reverse stock split May 21

First Trust NYSE Arca Biotech Index Fd(FBT.US)